Looking for these features could reduce biopsies and facilitate more timely screening.
COVID-19 vaccine-related adenopathies are a known entity, but in many instances, they can still give providers pause about what they’re seeing on a screening breast exam.
In a new article published July 26 in Clinical Imaging, a team of investigators from the Diagnostic Center for Women in Miami shared a pattern on screening that, when visualized, can bolster a radiologist's confidence in rendering a benign assessment.
“Knowing that the COVID-19 vaccine is administered intramuscularly in the deltoid muscle of the upper arm and understanding the lymphatic drainage pattern of the breast and upper extremity,” said the team led by Michael J. Plaza, M.D., a radiologist at the Center, “we suggest that a pattern of unilateral axillary lymphadenopathy involving the lateral, central, and/or apical groups with relative sparing of the anterior group is typical for vaccine-related lymphadenopathy.”
For their study, they used findings from a screening breast MRI conducted on a 63-year-old asymptomatic female patient. She received her second vaccine dose in her left arm six days prior to the scan.
These were their findings:
“Identifying this pattern of unilateral axillary adenopathy in the setting of ipsilateral COVID-19 vaccine administration and a negative screening breast MRI allows one to confidently give a benign assessment in keeping with a pragmatic approach,” the team said.
Consequently, they added, radiologists may be able to reduce the number of unneeded follow-ups and/or biopsies. This knowledge also pushes back against the practice of delaying breast MRI screening due to recent vaccinations.
Still, the team cautioned, providers should treat every instance with patients who have a history of cancer as an individual experience. Determine the course of action and treatment with a multi-disciplinary team based on cancer type, lymph node drainage pathway, and metastasis risk.
For more coverage based on industry expert insights and research, subscribe to the Diagnostic Imaging e-Newsletter here.
Leading Breast Radiologists Discuss the USPSTF Breast Cancer Screening Recommendations
May 17th 2024In recognition of National Women’s Health Week, Dana Bonaminio, MD, Amy Patel, MD, and Stacy Smith-Foley, MD, shared their thoughts and perspectives on the recently updated breast cancer screening recommendations from the United States Preventive Services Task Force (USPSTF).
Current Insights and Emerging Roles for Contrast-Enhanced Mammography
May 10th 2024In a recent lecture at the 2024 ARRS Annual Meeting, Jordana Phillips, MD, discussed the role of contrast-enhanced mammography in staging breast cancer, evaluating response to neoadjuvant chemotherapy and recalls from screening.
MRI-Based Deep Learning Algorithm Shows Comparable Detection of csPCa to Radiologists
May 8th 2024In a study involving over 1,000 visible prostate lesions on biparametric MRI, a deep learning algorithm detected 96 percent of clinically significant prostate cancer (csPCa) in comparison to a 98 percent detection rate for an expert genitourinary radiologist.